drugset / Trial / NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Timeline
- Start
- 2015-02-20
- Primary completion
- 2020-07-14
- Completion
- 2025-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |